# US 2019/0167572 A1 · Subcutaneous implant-type device for cell transplantation therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167572 A1
- Document ID: US20190167572A1
- Status: Published application
- Kind: A1
- Application number: 15/772,697
- Filed: 2016-11-07
- Published: 2019-06-06
- Earliest claimed: 2015-11-06
- Assignees: Tohoku University
- Applicants: Tohoku University
- Inventors: Toshiaki ABE; Nobuhiro NAGAI; Shinji YAMADA; Masafumi GOTO; Kozue IMURA; Hirokazu KAJI
- Web page: https://patentgrep.com/patent/US20190167572A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4816: {Wall or shell material}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A capsule device, which can induce vascular bed formation and formation of a space for cell transplantation in subcutaneous tissue in which the device is implanted, is provided. A sustained drug release capsule device, which is to be subcutaneously implanted for subcutaneous sustained release of an angiogenesis-inducing factor as well as formation of a vascular bed as a basis for cell transplantation and a space for cell transplantation in cell therapy, the capsule being made of a material which is not soluble in a biological body and does not adhere to a biological body, and having micropores for sustained release of the angiogenesis-inducing factor.

## Claims

### Claim 1

A sustained drug release capsule device, which is to be subcutaneously implanted for subcutaneous sustained release of an angiogenesis-inducing factor as well as formation of a vascular bed as a basis for cell transplantation and a space for cell transplantation in cell therapy, wherein the capsule is made of a material which is not soluble in a biological body and does not adhere to a biological body, and has micropores for sustained release of the angiogenesis-inducing factor.

### Claim 2 (depends on 1)

The sustained drug release capsule device of claim 1, wherein the material which is not soluble in a biological body and does not adhere to a biological body is selected from the group consisting of triethylene glycol dimethacrylate (TEGDM), tetraethylene glycol dimethacrylate, polytetramethylene glycol diacrylate (PTMG), polypropylene glycol diacrylate, isostearyl acrylate, urethane acrylate, methoxy polyethylene glycol acrylate, 2-hydroxy-3-acryloyloxy propyl methacrylate, dipropylene glycol diacrylate, tripropylene glycol diacrylate, 1,9-nonanediol diacrylate, 1,6-hexanediol diacrylate, 1,10-decanediol diacrylate, tricyclodecane dimethanol diacrylate, propoxylated bisphenol A diacrylate, 9,9-bis[4-(2-acryloyloxyethoxy)phenyl]fluorene, ethoxylated bisphenol A diacrylate, propoxylated ethoxylated bisphenol A diacrylate, and 2-hydroxy-3-acryloyloxy propyl methacrylate.

### Claim 3 (depends on 1)

The sustained drug release capsule device of claim 1, wherein the angiogenesis-inducing factor is selected from the group consisting of a basic fibroblast growth factor (bFGF), an acidic fibroblast growth factor (aFGF), a vascular endothelial growth factor (VEGF), a platelet-derived growth factor, a transforming growth factor-β (TGF-β), a hepatocyte growth factor (HGF), osteonectin, and angiopoietin.

### Claim 4 (depends on 1)

The sustained drug release capsule device of claim 1, which encapsulates the angiogenesis-inducing factor.

### Claim 5 (depends on 4)

The sustained drug release capsule device of claim 4, wherein the angiogenesis-inducing factor is mixed and pelletized with a water-soluble polymer.
